Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Abstract Background Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical decision making in only a small minority of screened...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Erlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, Cecilie J. Sandberg, Swapnil Potdar, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2019-12-01
Colecção:Clinical and Translational Medicine
Assuntos:
Glioblastoma
Recurrent glioblastoma
Glioblastoma stem cells
High-throughput drug screening
Drug sensitivity and resistance testing
Individualized medicine
Acesso em linha:http://link.springer.com/article/10.1186/s40169-019-0253-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados